Company intelligence / Profile preview

Morphocell Technologies

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

Morphocell has collected compelling preclinical efficacy and safety data for its ReLiver technology, with proof-of-concept studies completed in large animals. The company anticipates entering clinical trials within two years (from 2024).

Therapeutic areas: Gastroenterology
Modalities: Cell therapyStem cell-derived engineered tissues
Industry: Biotech

Drug pipeline

2 assets

micro-encapsulated hepatocytes

1 more asset in the full pipeline.

Request access →

Partnerships

BioSurfacesCHU Sainte-Justine

Beyond the preview

Go deeper on Morphocell Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphocell Technologies.

Explore the full profile